Arterial Wall Calcium Load in Pseudoxanthoma Elasticum (Ca-Art-PXE2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01731080|
Recruitment Status : Unknown
Verified November 2012 by University Hospital, Angers.
Recruitment status was: Recruiting
First Posted : November 21, 2012
Last Update Posted : November 21, 2012
|Condition or disease|
|Pseudoxanthoma Elasticum Type 2 Diabetes Chronic Kidney Disease|
In a previous work we have observed that patients suffering from PXE, a soft-tissue calcifying inherited autosomal disease, exhibited specific structural and functionnal features within the peripheral arteries. We now want to quantify and determine the preferential sites of the arterial wall calcification (Agatston score) between these patients compared to diabetics and patients with chronic renal insufficiency with mediacalcosis.
All variables will be collected from a cohort of PXE monitored in our PXE Health and Care centre at the university hospital of Angers. Quantification of the arterial wall calcium load will be performed using helicoidal CT-scan. These variables will be compared to the same measurements performed in type 2 diabetic and chronic kidney disease patients paired by age and gender.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Observational Model:||Case Control|
|Official Title:||Arterial Wall Calcium Load and Preferential Sites in Pseudoxanthoma Elasticum Versus Type 2 Diabetes and Chronic Kidney Disease.|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||July 2013|
|Estimated Study Completion Date :||July 2013|
Patients with genetically and clincally proven PXE
chronic kidney disease
Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
- calcification score [ Time Frame: after inclusion ]the level of arterial wall calcification determined by a Ct-scan and computed by the Agatston score
- site of calcification [ Time Frame: after inclusion ]the anatomical site of arterial wall calcification determined by a Ct-scan and computed by the Agatston score
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01731080
|Contact: Yannick LE CORRE, MD||33(2)firstname.lastname@example.org|
|Contact: Ludovic MARTIN, MD, PhD||33(2)email@example.com|
|Angers, Pays de la Loire, France, 49933|
|Contact: Ludovic MARTIN, MD, PhD 33(2)126.96.36.199 firstname.lastname@example.org|
|Contact: Georges LEFTHERIOTIS, MD, PhD 33(2)188.8.131.52 email@example.com|
|Principal Investigator: Yannick LE CORRE, MD|
|Sub-Investigator: Ludovic MARTIN, MD, PhD|
|Sub-Investigator: Georges LEFTHERIOTIS, MD, PhD|
|Sub-Investigator: Pierre ABRAHAM, MD, PhD|
|Sub-Investigator: Serge WILLOTEAUX, MD, PhD|
|Sub-Investigator: Jean-Francois SUBRA, MD, PhD|
|Sub-Investigator: Pierre-Henri DUCLUZEAU, MD|
|Principal Investigator:||Yannick LE CORRE, MD||Department of Dermatology, University Hospital of Angers, France|